Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
AACR Presentations Highlight BATTLE Trial as New Model for Biomarker-Based Drug Studies
April 06, 2011
The BATTLE trial was the first prospective, adaptively randomized study in pretreated non-small cell lung cancer patients that mandated tumor profiling with “real time” biopsies. The 255 patients in the trial were adaptively randomized to four arms — erlotinib, vandetanib, erlotinib plus bexarotene, or sorafenib — based on their biomarker profiles.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche
July 1, 2011 / ProteoMonitor - Clovis, Avila to Co-develop Targeted NSCLC Drug with Companion Test in Deal Worth up to $209M
May 26, 2010 / Pharmacogenomics Reporter - UNC Team Takes Proteomic Approach to Study Drug Resistance in Triple-Negative Breast Cancer
April 20, 2012 / ProteoMonitor - Biodesix Inks Deal to Test Veristrat in Phase III Clinical Trial for Kadmon Lung Cancer Drug
March 2, 2012 / ProteoMonitor - Ventana's Growing Companion Dx Focus Mirrors Parent Roche's Investment in Personalized Rx
January 18, 2012 / Pharmacogenomics Reporter